Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands

Hiroyuki Miyachi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The molecular pharmacological discovery of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) as the master regulator of lipid and lipoprotein homeostasis, and the rapid development of a parallel screening approach to evaluate activity towards other PPAR subtypes (PPARδ, and PPARγ) have provided an opportunity to develop novel PPARα-selective, PPARα/γ dual, and PPAR pan agonists. This review focuses on the molecular pharmacology of PPARα, and summarizes our current design, synthesis, and evaluation of subtype-selective PPARα agonists. The species selectivity of several classes of PPARα selective agonists in response to in vitro PPARα transactivation activity is also reported. These studies should help us to understand the structure-activity relationships and the mode of interaction between ligands and PPARα, and also help to create novel therapeutic choices for the treatment of metabolic disorders.

Original languageEnglish
Pages (from-to)803-813
Number of pages11
JournalYakugaku Zasshi
Volume124
Issue number11
DOIs
Publication statusPublished - Nov 2004
Externally publishedYes

Fingerprint

PPAR alpha
Peroxisome Proliferator-Activated Receptors
Ligands
Pharmacology
Structure-Activity Relationship
Cytoplasmic and Nuclear Receptors
Transcriptional Activation
Lipoproteins
Homeostasis

Keywords

  • Peroxisome proliferator-activated receptor (PPAR)
  • PPARα
  • Species selectivity

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands. / Miyachi, Hiroyuki.

In: Yakugaku Zasshi, Vol. 124, No. 11, 11.2004, p. 803-813.

Research output: Contribution to journalArticle

@article{d966207223ce42cb9d5ba1b5f217cf2c,
title = "Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands",
abstract = "The molecular pharmacological discovery of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) as the master regulator of lipid and lipoprotein homeostasis, and the rapid development of a parallel screening approach to evaluate activity towards other PPAR subtypes (PPARδ, and PPARγ) have provided an opportunity to develop novel PPARα-selective, PPARα/γ dual, and PPAR pan agonists. This review focuses on the molecular pharmacology of PPARα, and summarizes our current design, synthesis, and evaluation of subtype-selective PPARα agonists. The species selectivity of several classes of PPARα selective agonists in response to in vitro PPARα transactivation activity is also reported. These studies should help us to understand the structure-activity relationships and the mode of interaction between ligands and PPARα, and also help to create novel therapeutic choices for the treatment of metabolic disorders.",
keywords = "Peroxisome proliferator-activated receptor (PPAR), PPARα, Species selectivity",
author = "Hiroyuki Miyachi",
year = "2004",
month = "11",
doi = "10.1248/yakushi.124.803",
language = "English",
volume = "124",
pages = "803--813",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands

AU - Miyachi, Hiroyuki

PY - 2004/11

Y1 - 2004/11

N2 - The molecular pharmacological discovery of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) as the master regulator of lipid and lipoprotein homeostasis, and the rapid development of a parallel screening approach to evaluate activity towards other PPAR subtypes (PPARδ, and PPARγ) have provided an opportunity to develop novel PPARα-selective, PPARα/γ dual, and PPAR pan agonists. This review focuses on the molecular pharmacology of PPARα, and summarizes our current design, synthesis, and evaluation of subtype-selective PPARα agonists. The species selectivity of several classes of PPARα selective agonists in response to in vitro PPARα transactivation activity is also reported. These studies should help us to understand the structure-activity relationships and the mode of interaction between ligands and PPARα, and also help to create novel therapeutic choices for the treatment of metabolic disorders.

AB - The molecular pharmacological discovery of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) as the master regulator of lipid and lipoprotein homeostasis, and the rapid development of a parallel screening approach to evaluate activity towards other PPAR subtypes (PPARδ, and PPARγ) have provided an opportunity to develop novel PPARα-selective, PPARα/γ dual, and PPAR pan agonists. This review focuses on the molecular pharmacology of PPARα, and summarizes our current design, synthesis, and evaluation of subtype-selective PPARα agonists. The species selectivity of several classes of PPARα selective agonists in response to in vitro PPARα transactivation activity is also reported. These studies should help us to understand the structure-activity relationships and the mode of interaction between ligands and PPARα, and also help to create novel therapeutic choices for the treatment of metabolic disorders.

KW - Peroxisome proliferator-activated receptor (PPAR)

KW - PPARα

KW - Species selectivity

UR - http://www.scopus.com/inward/record.url?scp=16644370608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644370608&partnerID=8YFLogxK

U2 - 10.1248/yakushi.124.803

DO - 10.1248/yakushi.124.803

M3 - Article

VL - 124

SP - 803

EP - 813

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 11

ER -